Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind randomized placebo-controlled study

Abstract

Background: Previous studies showed that angiotensin-receptor blocker (ARB) therapy decreased proteinuria and possibly slowed the rate of renal function decline in patients with chronic proteinuric nephropathies. We performed a double-blind, randomized, placebo-controlled, multicenter study on the ARB valsartan in the treatment of patients with immunoglobulin A (IgA) nephropathy. Methods: From 6 centers, we recruited 109 patients with IgA nephropathy who had either: (1) proteinuria with protein greater than 1 g/d and serum creatinine level less than 2.8 mg/dL ( Results: There were 54 patients in the treatment group and 55 patients in the placebo group. Baseline clinical characteristics were similar between groups, although the treatment group had a marginally greater baseline GFR (87 ± 36 versus 78 ± 38 mL/min/1.73 m 2 [1.45 ± 0.60 versus 1.30 ± 0.63 mL/s/1.73 m 2 ]; P = 0.29) and less proteinuria (protein, 1.8 ± 1.2 versus 2.3 ± 1.7 g/d; P = 0.21) than the placebo group. Average blood pressures during the study were 92.7 ± 10.6 mm Hg in the treatment group and 100.9 ± 9.1 mm Hg in the placebo group ( P P = 0.18). Proteinuria decreased significantly in the treatment group (protein, 1.8 ± 1.2 to 1.2 ± 1.2 g/d; P = 0.03), but did not change in the placebo group. With multiple linear regression models, valsartan treatment resulted in a 33.0% decrease in proteinuria (95% confidence interval, 10.9 to 55.1) after adjusting for other confounding factors. There was a significant decrease in mean rate of GFR decrease in the valsartan-treated group (−5.62 ± 6.79 mL/min/y [−0.09 ± 0.11 mL/s/y]) compared with the placebo group (−6.98 ± 6.17 mL/min/y [−0.12 ± 0.10 mL/s/y]) throughout the study period after adjustment for average blood pressure and proteinuria ( P = 0.014). Conclusion: Valsartan significantly decreases proteinuria and slows renal deterioration in patients with IgA nephropathy after adjustment for confounding factors, notably blood pressure. The long-term benefit of valsartan needs to be confirmed with additional studies.